Symbiotec Pharma
SYMBIOTEC • Pharmaceuticals & Biotechnology
Last Price
₹1279.50
Market Cap
₹8.06K Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-10-16Sector: Symbiotec Pharma (SYMBIOTEC) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry. NSE sector rotation chart
Sharia rating: Symbiotec Pharma has no Sharia-compliance rating yet. Full list of halal NSE stocks
Price trend
No reading
We don't have enough data to measure this for Symbiotec Pharma right now.
Institutional activity
Positive
Trading patterns over recent weeks show some signs of institutions buying Symbiotec Pharma (buying score 3/10, selling score 1/10).
Model rank
Negative
Our model's 5-day return score puts Symbiotec Pharma ahead of 26% of NSE stocks. The model has low confidence in this score (47%).
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 2/10). Volume has been below normal for 6 days.
Price vs profits
Well above typical
The share price is 64× last year's profit per share — well above the typical range for NSE stocks (15–30×).
The wider Indian market is in a crisis regime — unusually sharp moves (model 99% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Symbiotec Pharma (SYMBIOTEC)
Symbiotec Pharma is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE899I01028). This page brings together the quantitative research signals our models compute for SYMBIOTEC: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Symbiotec Pharma's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.